share_log
Breakings ·  Sep 30 20:00
Mbx Biosciences Presents Mbx 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the Asbmr 2024 Annual Meeting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment